Importantly, these results have bearing on the development of alternative treatments for type II diabetes as until now, the pharmacological (both beneficial and deleterious) effects of the TZD drugs have been widely linked to the peroxisome proliferator-activated receptor gamma PPARγ [11]–[16]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.